NASDAQ : MENS
Jyong Biotech Ltd. — Key statistics
Healthcare · Biotechnology · Taiwan
Last price 1.88 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 139.56M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 139.56M |
| Enterprise Value | 156.93M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 20, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 74.23M |
| Shares Outstanding | 74.23M |
| Shares Change (YoY) | +2.02% |
| Shares Change (QoQ) | +3.49% |
| Owned by Insiders (%) | 63.70% |
| Owned by Institutions (%) | 0.72% |
| Float | 26.94M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.45 |
| Quick Ratio | 0.03 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.03 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -12.01% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 18.58% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$173,000 |
| Employee Count | 27 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | n/a |
| 52-Week Price Change | -96.24% |
| 50-Day Moving Average | 2.08 |
| 200-Day Moving Average | 2.16 |
| Relative Strength Index (RSI) | 45.55 |
| Average Volume (20 Days) | 41,770 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 213,264 |
| Short Previous Month | 222,116 |
| Short % of Shares Out | 0.29% |
| Short % of Float | 0.79% |
| Short Ratio (days to cover) | 4.46 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -2.61M |
| Pretax Income | -4.67M |
| Net Income | -4.67M |
| EBITDA | -2.51M |
| EBIT | -2.61M |
| Earnings Per Share (EPS) | -$0.06 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 1.18M |
| Total Debt | 18.55M |
| Net Cash | -17.37M |
| Net Cash Per Share | -$0.23 |
| Equity (Book Value) | -24.91M |
| Book Value Per Share | -0.34 |
| Working Capital | -19.27M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -3.04M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 100,000 |
| Net Borrowing | -24,000 |
| Free Cash Flow | -3.04M |
| FCF Per Share | -$0.04 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2.02% |
| Shareholder Yield | -2.02% |
| Earnings Yield | -3.40% |
| FCF Yield | -2.18% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |